

Presentation Title 报告标题:

Accelerating Lead Optimization Chemistry with In-depth Structure-Druggability (Drug-like property) Relationship (SDR) Studies

基于“结构-类药性”关联研究的先导化合物优化

Speaker 报告人:


Yaoqiu Zhu, Ph.D., Chief Research Investigator, MetabQuest Research and Consulting

朱耀球 博士 北京和济美代医药技术研究有限公司（美代研究） 首席研究员

Abstract 报告摘要:

ADME-Tox study has become an essential part of drug discovery research, aiming to build the necessary druggabilities ("drug-like" properties) into drug candidates with higher success probabilities in preclinical and clinical studies.

In-depth structure-druggability (drug-like property) relationship (SDR) studies can accelerate lead optimization chemistry programs in many ways: 1. Dial out soft spot quickly for lead modification; 2. Detect reactive/toxic metabolite and provide chemical strategy to minimize tox risk of the lead series; 3. Provide me-better approaches for follow-on program; 4. Identify animal species for tox studies of lead series; 5. Identify the correct in vitro system that predicts in vivo behaviors of lead series; 6. Track druggability behind structural progression of lead compound; 7. Address PK-PD discrepancy in animal studies; 8. Design and evaluate prodrug approaches for lead series; etc..



This seminar is based on case studies from different lead optimization programs at different stages demonstrating the assisting role of SDR studies and how to do in-depth SDR studies to accelerate lead optimization chemistry programs.

Invited Seminar 报告经历:

2010.08 Pharmaron, Beijing, China

2010.07 Tasly Pharmaceuticals, Tianjin, China

2009.11 Beijing Hanmi Pharm, Beijing, China

2009.10 7th Annual Congress of International Drug Discovery Science and Technology, Shanghai, China

2009.10 Chinese Medicinal Chemistry Symposium 2009, Wuhan, China

2009.09 Department of Chemistry, Northwestern University, Evanston, IL, USA

2009.07 Bridge Laboratories, Beijing, China

2009.07 BioDuro, Beijing, China

2009.05 Hutchison MediPharma, Shanghai, China

2009.05 Shanghai ChemPartner, Shanghai, China

2009.03 MicuRx Pharmaceuticals, Shanghai, China

2009.02 Shanghai Heng Rui Pharmaceuticals, Shanghai, China

2009.02 Egret Pharmaceutical, Shanghai, China

2008.12 Midwest BioResearch, Skokie, IL, USA

2008.12 Drug Metabolism Department, Takeda Global Research Center, Lake Forest, IL, USA

2008.11 Hit-to-lead Department, Abbott Laboratories, IL, USA

2008.11 Preclinical Drug Metabolism Department, Abbott, IL, USA

2008.11 Neuroscience Research Division, Abbott, IL, USA

2008.08 Medicinal Chemistry Department, Abbott Bioresearch Center, Worcester, MA, USA